LCLoïc Coutte

Loïc Coutte

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Loïc Coutte has a total of 110 co-authors. Here are the top co-authors by number of shared publications:

  • Camille Locht

    Institut Pasteur de Lille, Inserm U1019, CNRS UMR9017, Centre for Infection and Immunity of Lille, CHU Lille, Inserm, University of Lille, Lille, France

    12 shared publications
  • Rudy Antoine

    Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France

    9 shared publications
  • Camille Locht

    University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL - Centre for Infection and Immunity of Lille, 1, Rue du Prof, F-59019, Calmette, Lille, France

    7 shared publications
  • Françoise Jacob-Dubuisson

    University of Lille, Inserm, CNRS, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Center for Infection and Immunity of Lille, Lille, France

    6 shared publications
  • Anne-Sophie Debrie

    University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL - Centre for Infection and Immunity of Lille, 1, Rue du Prof, F-59019, Calmette, Lille, France

    5 shared publications
  • David Hot

    Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US41-UAR 2014, F-59000 Lille, France

    5 shared publications

Latest Publications

  • Open Access

    Nasal environment potentiates the pathogenicity of Bordetella pertussis

    by Dacine Osmani Raik, Anne-Sophie Debrie, Rudy Antoine, Stephanie Slupek, Maud Deny, Sophie Lecher, Anne-Sophie Lacoste, Jean-Michel Saliou, Jimmy Vandel, Estelle Chatelain, et al.

    Pertussis remains a major health concern, as acellular vaccines fail to prevent nasal infection and transmission. The nasal cavity is the primary niche for Bordetella pertussis colonization, but how this particular environment shapes bacterial pathogenicity remains poorly understood. Here we developed bacterial culture conditions that replicate the nasal environment, combining nasal-fluid-like transition metals concentrations with nasal cavity temperature. Using complementary transcriptomic and proteomic approaches, Dual RNA-sequencing, and in vitro and in vivo infection models, we assessed their impact on host-pathogen interactions. Nasal-like conditions reprogram B. pertussis into a state of increased virulence, conferring functional advantages for efficient bacterium-cell interactions and inducing physiological remodeling of human nasal epithelial cells. Finally, we showed that nasal preconditioning promotes efficient early B. pertussis colonization in mice. Altogether, these findings identify the nasal cavity as an instructive niche priming B. pertussis for efficient upper respiratory tract colonization following airborne transmission.

  • Open Access

    SphB1 export system for antigen presentation to the respiratory tract by a live pertussis vaccine

    by Lazara Elena Santiesteban-Lores, Dominique Raze, Violaine Dubois, Morgane Tardy, Anne-Sophie Debrie, Peter Goldstein, Loic Coutte, Camille Locht

    BPZE1 is a live attenuated vaccine currently in advanced clinical development for nasal immunization against pertussis. The ability of this vaccine to induce mucosal and systemic, humoral and cellular immunity make it an attractive mucosal delivery system for heterologous antigens to induce immunity especially in the respiratory tract. Here, we have developed a heterologous antigen expression system based on the pertactin-deficient BPZE1 derivative IB-V002 by using the SphB1 secretion system to present the SARS-CoV-2 nucleocapsid protein (N) as a model antigen to the respiratory mucosa. SphB1 is an autotransporter comprising a subtilisin-like passenger domain and a C-terminal ß-barrel domain. The passenger domain was replaced by the SARS-CoV-2 N protein. The recombinant gene was inserted into the urease locus of IB-V002 and placed under the control of the pertactin promoter and signal peptide. Immunoblot analyses indicated that the chimeric protein was produced and secreted by the recombinant strain named BT-V101. Mice intranasally immunized with BT-V101 induced N-specific IgG in serum and IFN-γ production by spleen cells. Importantly, a local N-specific CD8+ T cell response was observed in nose-associated lymphoid tissues by MHC class I tetramer staining. Additionally, immunization with BT-V101 efficiently primed mice to recombinant purified N protein given as a boost either intranasally or subcutaneously. These results demonstrate the suitability of the B. pertussis SphB1 secretion machinery to secret heterologous antigens for the development of a mucosal immunization vaccine platform with the induction of specific humoral and cellular, local, and systemic immune responses. KEY POINTS: • The SphB1 export system was used to secrete heterologous antigens by B. pertussis. • Recombinant B. pertussis induced systemic and local immunity to foreign antigens. • Recombinant B. pertussis efficiently primed immune responses to foreign antigens.

  • Open Access

    A new family of TonB-dependent copper transporters linked to respiratory oxidase function

    by Majda Hachmi, Manon Mirgaux, René Wintjens, Chloé Carassus, Pascal Arnoux, Gauthier Roy, Alex Rivera-Millot, Stéphanie Slupek, Anne-Sophie Debrie, Véronique Alaimo, et al.


  • Pertussis toxin-dependent and -independent protection by Bordetella pertussis against influenza

    by Thomas Belcher, Loïc Coutte, Anne-Sophie Debrie, Valentin Sencio, François Trottein, Camille Locht, Stephane Cauchi


  • Open Access

    Combined transcriptomic and ChIPseq analyses of the Bordetella pertussis RisA regulon

    by Loïc Coutte, Rudy Antoine, Stephanie Slupek, Camille Locht

    The regulation of Bordetella pertussis virulence is mediated by the two-component system BvgA/S, which activates the transcription of virulence-activated genes ( vag s). In the avirulent phase, the vag s are not expressed, but instead, virulence-repressed genes ( vrg s) are expressed, under the control of another two-component system, RisA/K. Here, we combined transcriptomic and chromatin immunoprecipitation sequencing (ChIPseq) data to examine the RisA/K regulon. We performed RNAseq analyses of RisA-deficient and RisA-phosphoablative B. pertussis mutants cultivated in virulent and avirulent conditions. We confirmed that the expression of most vrg s is regulated by phosphorylated RisA. However, the expression of some, including those involved in flagellum biosynthesis and chemotaxis, requires RisA independently of phosphorylation. Many RisA-regulated genes encode proteins with regulatory functions, suggesting multiple RisA regulation cascades. By ChIPseq analyses, we identified 430 RisA-binding sites, 208 within promoter regions, 201 within open reading frames, and 21 in non-coding regions. RisA binding was demonstrated in the promoter regions of most vrg s and, surprisingly, of some vag s, as well as for other genes not identified as vag s or vrg s. Unexpectedly, many genes, including some vag s, like prn , brpL , bipA, and cyaA , contain a BvgA-binding site and a RisA-binding site, which increases the complexity of the RisAK/BvgAS network in B. pertussis virulence regulation. IMPORTANCE: The expression of virulence-activated genes ( vag s) of Bordetella pertussis , the etiological agent of whooping cough, is under the transcriptional control of the two-component system BvgA/S, which allows the bacterium to switch between virulent and avirulent phases. In addition, the more recently identified two-component system RisA/K is required for the expression of B. pertussis genes, collectively named vrg s, that are repressed during the virulent phase but activated during the avirulent phase. We have characterized the RisA/K regulon by combined transcriptomic and chromatin immunoprecipitation sequencing analyses. We identified more than 400 RisA-binding sites. Many of them are localized in promoter regions, especially vrg s, but some were found within open reading frames and in non-coding regions. Surprisingly, RisA-binding sites were also found in promoter regions of some vag s, illustrating the previously underappreciated complexity of virulence regulation in B. pertussis .


  • Open Access

    Manufacture of a Stable Lyophilized Formulation of the Live Attenuated Pertussis Vaccine BPZE1

    by Marcel Thalen, Anne-Sophie Debrie, Loic Coutte, Dominique Raze, Ken Solovay, Keith Rubin, Nathalie Mielcarek, Camille Locht

    Current pertussis vaccines protect against disease, but not against colonization by and transmission of Bordetella pertussis, whereas natural infection protects against both. The live attenuated vaccine BPZE1 was developed to mimic immunogenicity of natural infection without causing disease, and in preclinical models protected against pertussis disease and B. pertussis colonization after a single nasal administration. Phase 1 clinical studies showed that BPZE1 is safe and immunogenic in humans when administered as a liquid formulation, stored at ≤−70 °C. Although BPZE1 is stable for two years at ≤−70 °C, a lyophilized formulation stored at ≥5 °C is required for commercialization. The development of a BPZE1 drug product, filled and lyophilized directly in vials, showed that post-lyophilization survival of BPZE1 depended on the time of harvest, the lyophilization buffer, the time between harvest and lyophilization, as well as the lyophilization cycle. The animal component-free process, well defined in terms of harvest, processing and lyophilization, resulted in approximately 20% survival post-lyophilization. The resulting lyophilized drug product was stable for at least two years at −20 °C ± 10 °C, 5 °C ± 3 °C and 22.5 °C ± 2.5 °C and maintained its vaccine potency, as evaluated in a murine protection assay. This manufacturing process thus enables further clinical and commercial development of BPZE1.


  • Open Access

    Combined RNAseq and ChIPseq Analyses of the BvgA Virulence Regulator of Bordetella pertussis

    by Loïc Coutte, Rudy Antoine, Stephanie Slupek, Luis Solans, Julien Derop, Amelie Bonnefond, David Hot, Camille Locht

    Bordetella pertussis , the etiological agent of whooping cough, remains a major global health problem. Despite the global usage of whole-cell vaccines since the 1950s and of acellular vaccines in the 1990s, it still is one of the most prevalent vaccine-preventable diseases in industrialized countries. Virulence of B. pertussis is controlled by BvgA/S, a two-component system responsible for upregulation of virulence-activated genes ( vag s) and downregulation of virulence-repressed genes ( vrg s). By transcriptome sequencing (RNAseq) analyses, we identified more than 270 vag s or vrg s, and chromatin immunoprecipitation sequencing (ChIPseq) analyses revealed 148 BvgA-binding sites, 91 within putative promoter regions, 52 within open reading frames, and 5 in noncoding regions. Some vag s, such as dnt and fhaL , do not contain a BvgA-binding site, suggesting indirect regulation. In contrast, several vrg s and some genes not identified by RNAseq analyses under laboratory conditions contain strong BvgA-binding sites, indicating previously unappreciated complexities of BvgA/S biology.


  • Coordinate regulation of virulence and metabolic genes by the transcription factor HbhR in Mycobacterium marinum

    by Dominique Raze, Jérôme Segers, Céline Mille, Stéphanie Slupek, Sophie Lecher, Loïc Coutte, Rudy Antoine, Lucie Ducrocq, Carine Rouanet, Ben J. Appelmelk, et al.

    Summary: The heparin‐binding hemagglutinin (HBHA) is a multifunctional protein involved in adherence of Mycobacterium tuberculosis to non‐phagocytic cells and in the formation of intracytosolic lipid inclusions. We demonstrate that the expression of hbhA is regulated by a transcriptional repressor, named HbhR, in Mycobacterium marinum. The hbhR gene, located upstream of hbhA, was identified by screening a transposon insertion library and detailed analysis of a mutant overproducing HBHA. HbhR was found to repress both hbhA and hbhR transcription by binding to the promoter regions of both genes. Complementation restored production of HBHA. RNA‐seq analyses comparing the mutant and parental strains uncovered 27 genes, including hbhA, that were repressed and 20 genes activated by HbhR. Among the former, the entire locus of genes coding for a type‐VII secretion system, including esxA, esxB and pe‐ppe paralogs, as well as the gene coding for PspA, present in intracellular lipid vesicles, was identified, as was katG, a gene involved in the sensitivity to isoniazid. The latter category contains genes that play a role in diverse functions, such as metabolism and resistance to oxidative conditions. Thus, HbhR appears to be a master regulator, linking the transcriptional regulation of virulence, metabolic and antibiotic sensitivity genes in M. marinum.


  • IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1 vaccine

    by Luis Solans, Anne-Sophie Debrie, Lisa Borkner, Nacho Aguiló, Anaïs Thiriard, Loic Coutte, Santi Uranga, François Trottein, Carlos Martín, Kingston H. G. Mills, et al.